Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Twist Bioscience's Enterprise Value is $8,137.4 Mil.
Twist Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-53.1 Mil. Therefore, Twist Bioscience's EV-to-OCF for today is -153.33.
The historical rank and industry rank for Twist Bioscience's EV-to-OCF or its related term are showing as below:
TWST'
s EV-to-OCF Range Over the Past 10 Years
Min: -169.81 Med: -17.91 Max: -2.86
Current: -153.33
During the past 10 years, the highest EV-to-OCF of Twist Bioscience was -2.86. The lowest was -169.81. And the median was -17.91.
TWST's EV-to-OCF is ranked better than 97.08% of 1406
companies
in the Biotechnology industry
Industry Median: -3.7
vs TWST: -153.33
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Twist Bioscience's PE Ratio (TTM) for today is calculated as:
Twist Bioscience's share price for today is $124.72.
Twist Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Twist Bioscience EV-to-OCF Related Terms
Twist Bioscience EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Twist Bioscience's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Twist Bioscience's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Twist Bioscience's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's EV-to-OCF falls into.
Twist Bioscience's current Enterprise Value is $8,137.4 Mil.
Twist Bioscience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience (TWST) has a EV-to-OCF of -153.33 as of Sep. 07, 2026. According to the industry distribution chart, Twist Bioscience ranks #41 out of 1406 companies in the Biotechnology industry, placing it in the top 2.9%.
Is Twist Bioscience's EV-to-OCF too high?
Twist Bioscience's current EV-to-OCF is -153.33. Based on the distribution chart, Twist Bioscience ranks #41 out of 1406 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Twist Bioscience has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's EV-to-OCF compare to QGEN and RDNT?
According to the Biotechnology industry distribution chart, Twist Bioscience ranks #41 out of 1406 companies for EV-to-OCF. This places Twist Bioscience in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Twist Bioscience's current EV-to-OCF is -153.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.11, compared to a current price of $124.72 — trading 134.8% above its estimated fair value. The current EV-to-OCF is -153.33. Twist Bioscience's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Twist Bioscience (TWST), the current EV-to-OCF is -153.33 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of $124.72 is trading 134.8% above its estimated GF Value™ of $53.11.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for TWST:
EV-to-OCF: -153.33
GF Value™: $53.11 vs. price of $124.72 (134.8% above fair value)
No single metric tells the full story. See the TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
69GF Score
Get the complete analysis for TWST
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWST has been successfully added to your 
